HIV-NAT 161

Project no.: HIV-NAT 161/HPV-019 PRI

A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix) administered intramuscularly according to a three-dose schedule (Day 0, Week 6, Month 6) in human immunodeficiency virus-infected (HIV+) female subjects aged 15 – 25 years, as compared to Merck’s HPV-6/11/16/18 vaccine (Gardasil)

Publications: in the process of submitting to journal